Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in

[News]

Peregrine Pharmaceuticals, Inc. has announced that updated preliminary data from the first stage of its Phase II trial evaluating bavituximab in combination with docetaxel showed that 10 of 14 (71%) evaluable breast cancer patients achieved an objective tumor response according to RECIST criteria.

More... (http://www.news-medical.net/?id=42102)